Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
CytomX Therapeutics (CTMX) Gets a Buy Rating from Mizuho Securities
02:50am, Friday, 28'th Feb 2020
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on CytomX Therapeutics (CTMX), with a price target of
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jounce Therapeutics (JNCE), Intercept Pharma (ICPT) and
Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on Jounce Therapeutics (
JNCE
–
Research Report
), Intercept Pharma (
ICPT
–
Research Report
) and For
Mizuho Securities Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
03:10pm, Wednesday, 26'th Feb 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS) today and set a price target of $22.00. The company's shares
Mizuho Securities Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
03:10pm, Wednesday, 26'th Feb 2020
Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Arcus Biosciences (
RCUS
–
Research Report
) today and set a price target of
$22.00
. The company’s shares closed last Monday at
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and BridgeBio Pharma (BBIO)
09:12am, Wednesday, 26'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fate Therapeutics (FATE) and BridgeBio Pharma (BBIO) with
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE) and BridgeBio Pharma (NASDAQ: BBIO)
09:12am, Wednesday, 26'th Feb 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fate Therapeutics
Xencor (XNCR) Receives a Buy from Mizuho Securities
05:16am, Tuesday, 25'th Feb 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Xencor (XNCR) today and set a price target of $52.00. The company's shares closed last
Xencor (XNCR) Receives a Buy from Mizuho Securities
05:16am, Tuesday, 25'th Feb 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Xencor (XNCR – Research Report) today and set a price
Mizuho Securities Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
10:07pm, Wednesday, 19'th Feb 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS) today and set a price target of $22.00. The company's shares
Mizuho Securities Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
10:07pm, Wednesday, 19'th Feb 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a
Analysts Offer Insights on Healthcare Companies: Molecular Templates (MTEM), Atricure (ATRC) and Fate Therapeutics (FATE)
10:06pm, Wednesday, 19'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Templates (MTEM), Atricure (ATRC) and Fate
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Templates
Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium
09:05pm, Wednesday, 19'th Feb 2020
Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commerciali
Xencor (XNCR) Receives a Buy from Mizuho Securities
02:28am, Tuesday, 18'th Feb 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Xencor (XNCR) yesterday and set a price target of $52.00. The company's shares closed
